206 related articles for article (PubMed ID: 21171821)
1. Epigenetic modulation of MAGE-A3 antigen expression in multiple myeloma following treatment with the demethylation agent 5-azacitidine and the histone deacetlyase inhibitor MGCD0103.
Moreno-Bost A; Szmania S; Stone K; Garg T; Hoerring A; Szymonifka J; Shaughnessy J; Barlogie B; Prentice HG; van Rhee F
Cytotherapy; 2011 May; 13(5):618-28. PubMed ID: 21171821
[TBL] [Abstract][Full Text] [Related]
2. MAGE-A1, MAGE-A3, and NY-ESO-1 can be upregulated on neuroblastoma cells to facilitate cytotoxic T lymphocyte-mediated tumor cell killing.
Bao L; Dunham K; Lucas K
Cancer Immunol Immunother; 2011 Sep; 60(9):1299-307. PubMed ID: 21626030
[TBL] [Abstract][Full Text] [Related]
3. Decitabine enhances tumor recognition by T cells through upregulating the MAGE-A3 expression in esophageal carcinoma.
Shi X; Chen X; Fang B; Ping Y; Qin G; Yue D; Li F; Yang S; Zhang Y
Biomed Pharmacother; 2019 Apr; 112():108632. PubMed ID: 30797153
[TBL] [Abstract][Full Text] [Related]
4. Induction of a CD8+ T-cell response to the MAGE cancer testis antigen by combined treatment with azacitidine and sodium valproate in patients with acute myeloid leukemia and myelodysplasia.
Goodyear O; Agathanggelou A; Novitzky-Basso I; Siddique S; McSkeane T; Ryan G; Vyas P; Cavenagh J; Stankovic T; Moss P; Craddock C
Blood; 2010 Sep; 116(11):1908-18. PubMed ID: 20530795
[TBL] [Abstract][Full Text] [Related]
5. Assessment of new HDAC inhibitors for immunotherapy of malignant pleural mesothelioma.
Bensaid D; Blondy T; Deshayes S; Dehame V; Bertrand P; Grégoire M; Errami M; Blanquart C
Clin Epigenetics; 2018; 10():79. PubMed ID: 29946373
[TBL] [Abstract][Full Text] [Related]
6. Promoter demethylation and histone acetylation mediate gene expression of MAGE-A1, -A2, -A3, and -A12 in human cancer cells.
Wischnewski F; Pantel K; Schwarzenbach H
Mol Cancer Res; 2006 May; 4(5):339-49. PubMed ID: 16687489
[TBL] [Abstract][Full Text] [Related]
7. HER-2, gp100, and MAGE-1 are expressed in human glioblastoma and recognized by cytotoxic T cells.
Liu G; Ying H; Zeng G; Wheeler CJ; Black KL; Yu JS
Cancer Res; 2004 Jul; 64(14):4980-6. PubMed ID: 15256472
[TBL] [Abstract][Full Text] [Related]
8. Intratumor heterogeneity of cancer/testis antigens expression in human cutaneous melanoma is methylation-regulated and functionally reverted by 5-aza-2'-deoxycytidine.
Sigalotti L; Fratta E; Coral S; Tanzarella S; Danielli R; Colizzi F; Fonsatti E; Traversari C; Altomonte M; Maio M
Cancer Res; 2004 Dec; 64(24):9167-71. PubMed ID: 15604288
[TBL] [Abstract][Full Text] [Related]
9. Epigenetically regulated clonal heritability of CTA expression profiles in human melanoma.
Fratta E; Sigalotti L; Colizzi F; Covre A; Nicolay HJ; Danielli R; Fonsatti E; Altomonte M; Calabrò L; Coral S; Maio M
J Cell Physiol; 2010 May; 223(2):352-8. PubMed ID: 20127705
[TBL] [Abstract][Full Text] [Related]
10. Epigenetic modulation combined with PD-1/PD-L1 blockade enhances immunotherapy based on MAGE-A11 antigen-specific CD8+T cells against esophageal carcinoma.
Wu Y; Sang M; Liu F; Zhang J; Li W; Li Z; Gu L; Zheng Y; Li J; Shan B
Carcinogenesis; 2020 Jul; 41(7):894-903. PubMed ID: 32529260
[TBL] [Abstract][Full Text] [Related]
11. Calreticulin acts as an adjuvant to promote dendritic cell maturation and enhances antigen-specific cytotoxic T lymphocyte responses against non-small cell lung cancer cells.
Liu X; Li J; Liu Y; Ding J; Tong Z; Liu Y; Zhou Y; Liu Y
Cell Immunol; 2016 Feb; 300():46-53. PubMed ID: 26702740
[TBL] [Abstract][Full Text] [Related]
12. Expansion of cancer germline antigen-specific cytotoxic T lymphocytes for immunotherapy.
Krishnadas DK; Wang Y; Sundaram K; Bai F; Lucas KG
Tumour Biol; 2017 Jul; 39(7):1010428317701309. PubMed ID: 28677424
[TBL] [Abstract][Full Text] [Related]
13. Melanoma associated antigen (MAGE)-A3 promotes cell proliferation and chemotherapeutic drug resistance in gastric cancer.
Xie C; Subhash VV; Datta A; Liem N; Tan SH; Yeo MS; Tan WL; Koh V; Yan FL; Wong FY; Wong WK; So J; Tan IB; Padmanabhan N; Yap CT; Tan P; Goh LK; Yong WP
Cell Oncol (Dordr); 2016 Apr; 39(2):175-86. PubMed ID: 26868260
[TBL] [Abstract][Full Text] [Related]
14. The cancer-testis antigens CT7 (MAGE-C1) and MAGE-A3/6 are commonly expressed in multiple myeloma and correlate with plasma-cell proliferation.
Jungbluth AA; Ely S; DiLiberto M; Niesvizky R; Williamson B; Frosina D; Chen YT; Bhardwaj N; Chen-Kiang S; Old LJ; Cho HJ
Blood; 2005 Jul; 106(1):167-74. PubMed ID: 15761016
[TBL] [Abstract][Full Text] [Related]
15. Cancer-testis antigen expression and its epigenetic modulation in acute myeloid leukemia.
Atanackovic D; Luetkens T; Kloth B; Fuchs G; Cao Y; Hildebrandt Y; Meyer S; Bartels K; Reinhard H; Lajmi N; Hegewisch-Becker S; Schilling G; Platzbecker U; Kobbe G; Schroeder T; Bokemeyer C; Kröger N
Am J Hematol; 2011 Nov; 86(11):918-22. PubMed ID: 21898529
[TBL] [Abstract][Full Text] [Related]
16. MAGE-A9 mRNA and protein expression in bladder cancer.
Picard V; Bergeron A; Larue H; Fradet Y
Int J Cancer; 2007 May; 120(10):2170-7. PubMed ID: 17290406
[TBL] [Abstract][Full Text] [Related]
17. Immunization with a recombinant MAGE-A3 protein after high-dose therapy for myeloma.
Szmania S; Gnjatic S; Tricot G; Stone K; Zhan F; Moreno A; Thuro B; Melenhorst J; Barrett J; Shaughnessy J; Old LJ; Barlogie B; Brichard VG; van Rhee F
J Immunother; 2007; 30(8):847-54. PubMed ID: 18049337
[TBL] [Abstract][Full Text] [Related]
18. Efficient lysis of epithelial ovarian cancer cells by MAGE-A3-induced cytotoxic T lymphocytes using rAAV-6 capsid mutant vector.
Batchu RB; Gruzdyn OV; Moreno-Bost AM; Szmania S; Jayandharan G; Srivastava A; Kolli BK; Weaver DW; van Rhee F; Gruber SA
Vaccine; 2014 Feb; 32(8):938-43. PubMed ID: 24406390
[TBL] [Abstract][Full Text] [Related]
19. Increased PRAME-specific CTL killing of acute myeloid leukemia cells by either a novel histone deacetylase inhibitor chidamide alone or combined treatment with decitabine.
Yao Y; Zhou J; Wang L; Gao X; Ning Q; Jiang M; Wang J; Wang L; Yu L
PLoS One; 2013; 8(8):e70522. PubMed ID: 23940586
[TBL] [Abstract][Full Text] [Related]
20. In vivo treatment with epigenetic modulating agents induces transcriptional alterations associated with prognosis and immunomodulation in multiple myeloma.
Maes K; De Smedt E; Kassambara A; Hose D; Seckinger A; Van Valckenborgh E; Menu E; Klein B; Vanderkerken K; Moreaux J; De Bruyne E
Oncotarget; 2015 Feb; 6(5):3319-34. PubMed ID: 25669970
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
